Additionally, Onyx has requested priority review of the application, which reduces the time the FDA takes to review a new drug application.
Onyx Research and Development and Technical Operations executive vice president Ted Love said they believe the efficacy and safety data within the NDA submission provide a compelling basis for accelerated approval of carfilzomib in the relapsed and refractory treatment setting.